Skip to main content
Observer Directory · Verified Members

The AimwellBio Observer network.

Credentialed biopharma professionals, researchers, and practitioners who have verified institutional access and opted into public listing. Observer access is free.

Public listings open at 100 verified members.

The directory is not yet public. To connect with verified Observers directly, reach us at:

corporate@aimwellbio.com
Where Observers stand

Observer is the front door. Here’s the ladder past it.

Observer access is free and verified — 5 source-traced verdicts, AIMN:ATLAS read access, and a public profile are active today. Your signal feed, watchlist, and dossiers activate during onboarding as the engine ships. Each seat above raises what you can do.

Active now
Observer · Free
5 verdicts, Atlas read access, and a verified public profile — delivered today.
Pathway
Contributor
Submit signals and review claims with the FHIN cohort. The seat for shaping the standard.
Become a Contributor →
Upgrade
Member
Higher verdict volume and saved-work surfaces for practitioners running decisions weekly.
See Member tier →
Upgrade
Signal
Team-scale verdict volume; watchlist, dossier, and competitor surfaces as they activate.
See Signal tier →

Command tier is sales-assisted. Request Command access →

Follow a topic

The areas with a curated corpus behind them.

Counts and last-compiled dates read straight from the dataset on disk — sources are PubMed, ClinicalTrials.gov, FDA, and SEC EDGAR. A scheduled-refresh, curated corpus, compiled on a schedule.

Loading the curated corpus…
Curated corpus
9 therapeutic areas
Oncology, Renal, Metabolic, Wound-Care, Neurology, Cardiovascular, ccRCC, Diabetes, Rare-Disease — sourced from PubMed, ClinicalTrials.gov, FDA, and SEC EDGAR.
Before the standard is visible

The serious people are organizing here first.

A verified network is only as strong as who is in it. If a colleague meets the credentialing bar, send them the door — no points, no referral bonus, just a stronger room. That is the only incentive we would stand behind.

Email a colleague Share on LinkedIn